BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 33037645)

  • 41. Risk of Oral and Upper Gastrointestinal Cancers in Persons With Positive Results From a Fecal Immunochemical Test in a Colorectal Cancer Screening Program.
    van der Vlugt M; Grobbee EJ; Bossuyt PM; Bos ACRK; Kuipers EJ; Lansdorp-Vogelaar I; Spaander MCW; Dekker E
    Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1237-1243.e2. PubMed ID: 29427732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme.
    de Klerk CM; Wieten E; Lansdorp-Vogelaar I; Bossuyt PM; Spaander MC; Dekker E
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):111-118. PubMed ID: 30497962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Screening for colorectal cancer and advanced colorectal neoplasia in kidney transplant recipients: cross sectional prevalence and diagnostic accuracy study of faecal immunochemical testing for haemoglobin and colonoscopy.
    Collins MG; Teo E; Cole SR; Chan CY; McDonald SP; Russ GR; Young GP; Bampton PA; Coates PT
    BMJ; 2012 Jul; 345():e4657. PubMed ID: 22833618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Participation in a population-based screening for colorectal cancer using the faecal immunochemical test decreases mortality in 5 years.
    Idigoras Rubio I; Arana-Arri E; Portillo Villares I; Bilbao Iturribarrria I; Martínez-Indart L; Imaz-Ayo N; de la Cruz M; de Castro V; López de Munain A; Torrejón Perez I; Gutiérrez-Ibarluzea I
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):197-204. PubMed ID: 30543575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Do socioeconomic factors play a role in nonadherence to follow-up colonoscopy after a positive faecal immunochemical test in the Flemish colorectal cancer screening programme?
    Hoeck S; van de Veerdonk W; De Brabander I
    Eur J Cancer Prev; 2020 Mar; 29(2):119-126. PubMed ID: 31724969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis.
    Wieten E; Schreuders EH; Grobbee EJ; Nieboer D; Bramer WM; Lansdorp-Vogelaar I; Bruno MJ; Kuipers EJ; Spaander MCW
    Gut; 2019 May; 68(5):873-881. PubMed ID: 29934436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of One versus Two Fecal Immunochemical Tests in the Detection of Colorectal Neoplasia in a Population-Based Colorectal Cancer Screening Program.
    Moosavi S; Enns R; Gentile L; Gondara L; McGahan C; Telford J
    Can J Gastroenterol Hepatol; 2016; 2016():5914048. PubMed ID: 28044123
    [No Abstract]   [Full Text] [Related]  

  • 48. Interval faecal occult blood testing in a colonoscopy based screening programme detects additional pathology.
    Bampton PA; Sandford JJ; Cole SR; Smith A; Morcom J; Cadd B; Young GP
    Gut; 2005 Jun; 54(6):803-6. PubMed ID: 15888788
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Gender-specific cut-offs in colorectal cancer screening with FIT: Increased compliance and equal positivity rate.
    Blom J; Löwbeer C; Elfström KM; Sventelius M; Öhman D; Saraste D; Törnberg S
    J Med Screen; 2019 Jun; 26(2):92-97. PubMed ID: 30336730
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study.
    Oort FA; van Turenhout ST; Coupé VM; van der Hulst RW; Wesdorp EI; Terhaar sive Droste JS; Larbi IB; Kanis SL; van Hengel E; Bouman AA; Meijer GA; Mulder CJ
    BMC Cancer; 2011 Oct; 11():434. PubMed ID: 21985604
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Participation in Competing Strategies for Colorectal Cancer Screening: A Randomized Health Services Study (PICCOLINO Study).
    Pilonis ND; Bugajski M; Wieszczy P; Rupinski M; Pisera M; Pawlak E; Regula J; Kaminski MF
    Gastroenterology; 2021 Mar; 160(4):1097-1105. PubMed ID: 33307024
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cost-effectiveness of the faecal immunochemical test at a range of positivity thresholds compared with the guaiac faecal occult blood test in the NHS Bowel Cancer Screening Programme in England.
    Murphy J; Halloran S; Gray A
    BMJ Open; 2017 Oct; 7(10):e017186. PubMed ID: 29079605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Colon capsule endoscopy in colorectal cancer screening: a randomised controlled trial.
    Kaalby L; Deding U; Kobaek-Larsen M; Havshoi AV; Zimmermann-Nielsen E; Thygesen MK; Kroeijer R; Bjørsum-Meyer T; Baatrup G
    BMJ Open Gastroenterol; 2020 Jun; 7(1):. PubMed ID: 32601101
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differences in diagnostic activity in general practice and findings for individuals invited to the danish screening programme for colorectal cancer: a population-based cohort study.
    Juul JS; Andersen B; Laurberg S; Carlsen AH; Olesen F; Vedsted P
    Scand J Prim Health Care; 2018 Sep; 36(3):281-290. PubMed ID: 29929415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of a card collection-based faecal immunochemical test in screening for colorectal cancer using a two-tier reflex approach.
    Fraser CG; Mathew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Gut; 2007 Oct; 56(10):1415-8. PubMed ID: 17309886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prescription drugs associated with false-positive results when using faecal immunochemical tests for colorectal cancer screening.
    Ibáñez-Sanz G; Garcia M; Rodríguez-Moranta F; Binefa G; Gómez-Matas J; Domènech X; Vidal C; Soriano A; Moreno V;
    Dig Liver Dis; 2016 Oct; 48(10):1249-54. PubMed ID: 27378703
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.
    Ribbing Wilén H; Blom J; Höijer J; Hultcrantz R
    J Gastroenterol Hepatol; 2019 Jan; 34(1):103-112. PubMed ID: 29968937
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening.
    Stegeman I; van Doorn SC; Mundt MW; Mallant-Hent RC; Bongers E; Elferink MA; Fockens P; Stroobants AK; Bossuyt PM; Dekker E
    Cancer Epidemiol; 2015 Jun; 39(3):388-93. PubMed ID: 25910865
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Priority stratification for colonoscopy based on two-sample faecal immunochemical test screening: results from a cross-sectional study at an endoscopy clinic in Japan.
    Toyoshima O; Yamaji Y; Nishizawa T; Yoshida S; Yamada T; Kurokawa K; Obata M; Kondo R; Toba M; Koike K
    BMJ Open; 2021 May; 11(5):e046055. PubMed ID: 34011594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Classifying interval cancers as false negatives or newly occurring in fecal immunochemical testing.
    Hsu WF; Hsu CY; Yen AM; Chen SL; Chiu SY; Fann JC; Lee YC; Chiu HM; Chen HH
    J Med Screen; 2021 Sep; 28(3):286-294. PubMed ID: 33461420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.